PROKIDNEY CORP
PROKNASDAQTrading Snapshot
- Day Range
- $1.47 – $1.49
- 52-Week Range
- $1.45 – $3.48
- Volume
- $2.81B
- Avg Volume
- $2.11B
- Shares Outstanding
- 302.1M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $893,000
- Last Q Revenue
- $150,000
- P/E Ratio
- —
- P/S Ratio
- 574.2x
- EPS (TTM)
- $-0.53
- Dividend Yield
- —
Why Investors Own PROK
- ✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PROKIDNEY CORP
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.